Opaleye Management’s BridgeBio Pharma BBIO Stock Holding History

Opaleye Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-18,319	Closed	-$1.4M	–	56
2025 Q4	$1.4M	Buy	+18,319	New	+$1.2M	0.18%	48
2022 Q1	–	Sell	-328,100	Closed	-$5.47M	–	46
2021 Q4	$5.47M	Sell	328,100 -183,400	-36%	-$7.76M	1.16%	28
2021 Q3	$24M	Sell	511,500 -5,650	-1%	-$303K	4.48%	7
2021 Q2	$31.5M	Sell	517,150 -66,617	-11%	-$3.8M	5.24%	4
2021 Q1	$36M	Buy	+583,767	New	+$38.2M	5.28%	4

Other funds holding BBIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Opaleye Management's BBIO Position: Q1 2026 in Review

Opaleye Management sold out of BridgeBio Pharma (BBIO) in Q1 2026, closing a stake of 18,319 shares — an estimated $1.4M sold.

Opaleye Management first reported a position in BBIO in Q1 2021 and held it in 5 quarters. The position peaked at $36M in Q1 2021. 460 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

Opaleye Management reported no remaining BridgeBio Pharma position as of Q1 2026 after selling out during the quarter.
Opaleye Management sold 18,319 BridgeBio Pharma shares in Q1 2026, an estimated $1.4M.
Opaleye Management first reported a position in BridgeBio Pharma in Q1 2021 and held it in 5 quarters.
Opaleye Management's BridgeBio Pharma position peaked at $36M in Q1 2021.
460 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Opaleye Management's 13F filing for Q1 2026, filed 15 May 2026.